Diabetes mellitus as a risk factor for SARS-CoV-2 test positivity in Mexico: A propensity score matched study.


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 18 04 2021
revised: 13 06 2021
accepted: 09 07 2021
pubmed: 24 7 2021
medline: 30 10 2021
entrez: 23 7 2021
Statut: ppublish

Résumé

We sought to investigate whether individuals with diabetes have a higher likelihood of testing positive for SARS-CoV-2, as a proxy for infection risk, than individuals without diabetes. We conducted a cross-sectional study of publicly available data among a Mexican population, totaling 2,314,022 adults ≥ 18 years who underwent SARS-CoV-2 testing between March 1 and December 20, 2020. We used 1:1 nearest neighborhood propensity score matching by diabetes status to account for confounding among those with and without diabetes. In the overall study population, 1,057,779 (45.7%) individuals tested positive for SARS-CoV-2 and 270,486 (11.7%) self-reported diabetes. After propensity score matching, patient characteristics were well-balanced, with 150,487 patients in the diabetes group (mean [SD] age 55.9 [12.7] years; 51.3% women) and 150,487 patients in the no diabetes group (55.5 [13.3] years; 50.3% women). The strictest matching algorithm (1:1 nearest neighbor) showed that compared to individuals without diabetes, having diabetes was associated with 9.0% higher odds of having a positive SARS-CoV-2 test (OR 1.09 [95% CI: 1.08-1.10]). Presence of diabetes was associated with higher odds of testing positive for SARS-CoV-2, which could have important implications for risk mitigation efforts for people with diabetes at risk of SARS-CoV-2 infection.

Identifiants

pubmed: 34298043
pii: S0168-8227(21)00313-2
doi: 10.1016/j.diabres.2021.108953
pmc: PMC8331361
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108953

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR002542
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007028
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest DJW reports serving on a data monitoring committee for Novo Nordisk. JBM reports serving as an Academic Associate for Quest Diagnostics. All other authors declare no competing interests.

Références

Diabetes. 1990 Mar;39(3):271-5
pubmed: 2407580
JAMA. 2003 Jun 4;289(21):2801-9
pubmed: 12734147
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
BMJ. 2020 Dec 11;371:m4809
pubmed: 33310819
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Diabetes Care. 2021 Feb;44(2):526-532
pubmed: 33268335
Bull World Health Organ. 2021 Mar 01;99(3):209-219B
pubmed: 33716343
Menopause. 2014 Aug;21(8):861-8
pubmed: 24496083
Immunol Lett. 2000 Nov 1;74(3):239-44
pubmed: 11064109
Diabetes Care. 2020 Oct;43(10):e127-e128
pubmed: 32796010
Int J Equity Health. 2020 Jul 29;19(1):126
pubmed: 32727486
Diabetes Care. 2020 Dec;43(12):2938-2944
pubmed: 32847827
Clin Infect Dis. 2005 Aug 1;41(3):281-8
pubmed: 16007521
Diabetes Care. 2018 Mar;41(3):513-521
pubmed: 29330152
PLoS One. 2021 Aug 31;16(8):e0256447
pubmed: 34464393
Curr Med Res Opin. 2016 Jul;32(7):1243-52
pubmed: 26986190
Lancet Infect Dis. 2013 Sep;13(9):752-61
pubmed: 23891402
Diabetes Care. 2021 Feb;44(2):373-380
pubmed: 33208487
BMC Infect Dis. 2018 Feb 5;18(1):67
pubmed: 29402218
PLoS One. 2020 Apr 16;15(4):e0230752
pubmed: 32298264
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32474598
MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):820
pubmed: 23051613
Diabet Med. 1997 Jan;14(1):29-34
pubmed: 9017350
Salud Publica Mex. 2020 Jan-Feb;62(1):50-59
pubmed: 31869561

Auteurs

Jacqueline A Seiglie (JA)

Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Edson Serván-Mori (E)

Center for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico. Electronic address: eservan@insp.mx.

Jennifer Manne-Goehler (J)

Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

James B Meigs (JB)

Department of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

J Jaime Miranda (JJ)

CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru; The George Institute for Global Health, Sydney, Australia.

Sandra G Sosa-Rubí (SG)

Center for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico.

Omar Silverman-Retana (O)

Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.

Deborah J Wexler (DJ)

Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Veronika J Wirtz (VJ)

Department of Global Health, Boston University School of Public Health, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH